title: Survival of patients who develop solid tumors following hematopoietic stem cell transplantation.
abstract: Allogeneic hematopoietic cell transplantation is associated with late adverse effects of therapy, including secondary solid cancers. Most reports address risk factors; however, outcomes after secondary solid cancer development are incompletely described. Our objective was to estimate survival probabilities for transplant recipients dependent on secondary solid cancer subtype. We used a previously identified and published cohort who developed secondary solid cancers following allogeneic transplant. Follow-up for these 112 previously identified patients was extended and their survival probabilities were studied. Median duration of follow-up from the development of secondary cancer for survivors was 11.9 years (range: 0.8-23.4) and 75% were followed >7.0 years. The 5- and 10-year overall survival probabilities were 50% (95% confidence interval (CI): 41-60) and 46% (95% CI: 37-57), respectively. Overall survival varied by secondary cancer type. Secondary cancer was the cause of death in most patients who died following development of melanoma, central nervous system, oral cavity, thyroid, lung, lower gastrointestinal tract and bone cancers. Extended follow-up allowed for the most comprehensive longitudinal evaluation to date of this rare condition. These findings will enhance clinicians' ability to predict outcomes and counsel transplant survivors who develop secondary solid cancers.
authors.affiliation: Division of Cancer Survivorship, Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Ehrhardt
authors.affiliation: Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA.|CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Froedtert and the Medical College of Wisconsin Clinical Cancer Center, Milwaukee, WI, USA.
authors.forename: R
authors.initials: R
authors.lastname: Brazauskas
authors.affiliation: CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Froedtert and the Medical College of Wisconsin Clinical Cancer Center, Milwaukee, WI, USA.
authors.forename: W
authors.initials: W
authors.lastname: He
authors.affiliation: CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Froedtert and the Medical College of Wisconsin Clinical Cancer Center, Milwaukee, WI, USA.
authors.forename: J D
authors.initials: JD
authors.lastname: Rizzo
authors.affiliation: CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Froedtert and the Medical College of Wisconsin Clinical Cancer Center, Milwaukee, WI, USA.
authors.forename: B E
authors.initials: BE
authors.lastname: Shaw
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D009928:Organ Specificity; D012189:Retrospective Studies; D015996:Survival Rate